News

 The collaboration will bring together Gubra’s expertise in the design, synthesis, characterization and in in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the development of

The Israeli pharma firm said that fremanezumab showed statistically significant and clinically meaningful results in the phase 3 studies in chronic (CM) and episodic migraine (EM). It added

The loan agreement is operated under the European Fund of Strategic Investments ("EFSI"). EFSI is an essential pillar of the Investment Plan for Europe ("IPE"), under which the

The approval has been granted for cemiplimab to treat adults with metastatic CSCC and adults with locally advanced and unresectable CSCC. CSCC is claimed to be the second

The company also revealed that it will be shuttering its Bridgewater research and development office in New Jersey along with the Lilly China Research and Development Center in

The Phase 2 trial achieved its primary endpoint prior to the completion of enrollment The trial protocol requires four confirmed, partial responses, per RECIST 1.1 criteria, out of

Upon exercise of this option and transition of the programme, GSK will assume responsibility for all development, manufacturing and commercialisation activities for the asset.  Adaptimmune will receive up

The drug showed a statistically-significant improvement in lung function in patients with moderate to very severe stable COPD compared against individual component that included either aclidinium bromide or formoterol.

The settlement with the US federal government is for resolving claims that the Danish multinational pharma failed to comply with the US Food and Drug Administration (FDA)-mandated Risk